Vincerx Pharma, Inc. (VINC): Price and Financial Metrics
GET POWR RATINGS... FREE!
VINC Stock Price Chart Interactive Chart >
VINC Price/Volume Stats
| Current price | $1.28 | 52-week high | $8.03 |
| Prev. close | $1.33 | 52-week low | $0.63 |
| Day low | $1.24 | Volume | 101,800 |
| Day high | $1.34 | Avg. volume | 87,578 |
| 50-day MA | $0.90 | Dividend yield | N/A |
| 200-day MA | $1.41 | Market Cap | 27.12M |
Vincerx Pharma, Inc. (VINC) Company Bio
Vincerx Pharma, Inc. operates as a clinical-stage life sciences company. The Company focuses on developing VIP152 inhibits PTEFb phosphorylation of RNA polymerase II (RNAPII), thereby preventing transcription elongation and blocking expression of genes that drive cancer. Vincerx Pharma serves customers worldwide.
Latest VINC News From Around the Web
Below are the latest news stories about VINCERX PHARMA INC that investors may wish to consider to help them evaluate VINC as an investment opportunity.
What Could Change After Vincerx Pharma Inc. (NASDAQ: VINC) Gains 35.71% From The High-Point?Vincerx Pharma Inc. (NASDAQ:VINC)’s traded shares stood at 0.41 million during the last session. At the close of trading, the stock’s price was $0.98, to imply an increase of 11.41% or $0.1 in intraday trading. The VINC share’s 52-week high remains $10.59, putting it -980.61% down since that peak but still an impressive 35.71% since … What Could Change After Vincerx Pharma Inc. (NASDAQ: VINC) Gains 35.71% From The High-Point? Read More » |
Immix, Avidity top healthcare gainers; Vincerx, Yumanity lead losers'' packImmix Biopharma (IMMX) +69%. Avidity Biosciences RNA +37%. Vincerx Pharma (VINC) -21%. Yumanity Therapeutics (YMTX) -16%. |
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cancer models VIP236 first-in-human study in advanced or metastatic solid tumors anticipated to commence in Q1 2023 PALO ALTO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet med |
Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor TypesIn a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was observed in patients with double-hit diffuse large B-cell lymphoma (DH-DLBCL) and other B-cell malignancies with a 30-mg dose level while maintaining a favorable safety profile Clinical trial to evaluate enitociclib in combination with venetoclax and prednisone (NIH sponsored) anticipated to commence in Q |
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin) VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine in an acute myeloid leukemia (AML) mouse model VIP943 IND-enabling studies continu |
VINC Price Returns
| 1-mo | 23.08% |
| 3-mo | 19.63% |
| 6-mo | -7.25% |
| 1-year | -81.18% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 25.49% |
| 2022 | -89.99% |
| 2021 | -51.27% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...